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for 40% of decisions, were compared with those of three major HTA agencies: CADTH, 
NICE and PBAC. HTA reports and meeting transcripts were analysed and categorised 
by date, therapy area, decision, rationale, and pricing decision. Resubmissions or those 
not assessed by the western HTA agencies were excluded. Results: A total of 65 NHI 
reports were identified. Of these 26 reported decisions on oncology or cardiovascular 
drugs, 12 were excluded (3 resubmissions, 9 not reviewed by the other agencies). Prior 
to 2GNHI, 4 out of 5 decisions were positive, or 80% approval rate, while after, only 
4 out of 9 were positive, a 44% approval rate. Prior to 2GNHI, all NHI reimbursement 
decisions identified (6) matched CADTH, NICE, and PBAC. After 2GNHI, only 6/9 or 
66% matched. Clinical effectiveness and budget impact were most cited in reim-
bursement rejections. For example Zytiga, NHI appreciated the cost-effectiveness 
but stated budget impact was too high, issuing a negative recommendation, contrary 
to the other agencies. Interestingly, a ‘local’ product was recommended for limited 
reimbursement even though budget impact was high. ConClusions: Since imple-
mentation of Taiwan’s NHI reforms in January 2013, cardiovascular and oncology drug 
approvals dropped by 36% and agreements with western agencies down 34%, placing 
an emphasis on budget impact. However, this analysis was constrained by its small 
sample size, and limited therapy areas.
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objeCtives: Phase III, randomised controlled trials remain the gold standard 
for health technology assessment (HTA) submissions. Data sets may be sup-
plemented with other sources (e.g. Phase II trials, observational studies, mixed 
treatment comparisons). However, the influence of expanded data sets on HTA 
appraisals is unclear. Methods: We reviewed recent National Institute for 
Health and Care Excellence (NICE; England and Wales) oncology drug submissions 
to determine the frequency and type of expanded data sets. We then evaluated 
the influence of expanded data on agency decisions. A similar review of submis-
sions to the Australian Pharmaceutical Benefits Advisory Committee (PBAC) was 
performed. Results: There were 30 relevant appraisals on the NICE website 
covering a range of cancer types. Of these, 14/30 made use of expanded data sets 
featuring Phase II trials, observational studies, meta-analyses and/or mixed treat-
ment comparisons among other sources. Reasons for using expanded data sets 
included: agency concerns over Phase III studies, lack of long-term or head-to-head 
data and limited Phase III data. Where additional data were included, around one 
third (5/14 cases, 35.7%; 5/30 [16.7%] overall) appeared to have directly influenced 
the final decision. Overall, positive appraisals were less frequent for submissions 
that featured expanded data sets compared with submissions featuring Phase III 
data only (2/14 [14.3%] versus 9/16 [56.3%]). Comparable to NICE, 2/10 (20%) of PBAC 
submissions were influence by expanded data sets, although cost-effectiveness data 
were crucial for PBAC approval overall. ConClusions: We found that expanded 
data sets feature in nearly half of recent NICE oncology HTA assessments. However, 
additional data appeared to influence only one in five appraisals by NICE and PBAC. 
Expanded data sets have a place in contributing to HTA decision making, but overall, 
rigorous Phase III RCT data remain essential to obtaining a positive HTA appraisal.
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objeCtives: Since January 2009, NICE in the UK allows end of life (EOL) treatments 
to exceed the upper end (£30,000/QALY) of the threshold range for incremental 
cost-effectiveness ratios (ICERs) by using higher weights for EOL life-years. With 
discussions surrounding the concept and implementation, and the introduction of 
the value based assessment framework, the aim of this study was to review NICE 
technology appraisals (TAs) in oncology to assess the interpretation, implementa-
tion and implications of the criteria. Methods: All completed TAs in oncology 
since 2009 were searched. When multiple submissions of the same TA were made, 
the latest were selected. Data were extracted to capture details of the appraisal 
(e.g. treatment, indication and decision), the consideration of the five different 
EOL criteria (applicability, interpretation, effect on the decision) and the method 
of implementation (weighting, threshold). Results: 61 TAs, including six multi-
ple technology appraisals, assessing 71 technologies were reviewed. EOL criteria 
were considered in 40 TAs covering 44 technologies. EOL weighting was considered 
appropriate for 36% of technologies. Most technologies fulfilled the criterion of 
< 24 month life expectancy (rejected in 14%), extension of life by ≥ 3 months or 
robustness of its calculation was the most common cause of rejection (32%/25% 
respectively). These criteria were inconsistently applied, using different methods 
(e.g. medians, restricted means from extrapolation, means from trial or model). The 
criterion of small population favoured technologies with limited indication (rejec-
tion 20%). Earlier TAs presented weight calculations, while later TAs only presented 
ICERs. ConClusions: Although aiming for greater transparency, the criteria left 
a large scope for interpretation in the decision making. Also, with the emphasis 
from applying higher weights to EOL life-years shifting to a differential threshold 
for certain indications, the original idea of considering wider societal preferences 
seem to have been neglected, that the new guidance should remedy.
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be issued a “do not recommend” decision than non-oncology reviews (56% vs. 16%, 
p< . 001). Over time, there was no significant trend in rates of “do not recommend” 
decisions for non-oncology reviews and oncology reviews, though rates of “do not 
recommend” decisions have increased for oncology reviews since 2008. There were no 
differences in the rates of “recommend” and “recommend with restriction” decisions 
between oncology and non-oncology reviews (p= . 87). Over time there was a signifi-
cant decrease in the rates of “recommend with restrictions” decisions for oncology 
reviews (p= . 07), but no statistical trend in non-oncology reviews. ConClusions: 
NICE was more likely to issue a “do not recommend” decision for oncology reviews 
than for non-oncology reviews, but there was no difference in the overall rates of 
“recommend with restrictions” decisions. Over time, NICE appears to be replacing 
“recommend with restriction” decisions with “do not recommend” decisions in oncol-
ogy reviews, but this did not pass traditional significance levels.
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Nowadays, economic evaluation has been increasingly used in health care decision-
making in Brazil. The Brazilian economic evaluation literature in cancerology is 
unknown. objeCtives: This systematic review aims to identify and characterize 
the economic evaluation studies in cancerology conducted in Brazil. Methods: 
Ten online databases (MEDLINE (PubMed), EMBASE, Latin American and Caribbean 
Literature on Health Sciences Database (LILACS), Scientific Electronic Library Online 
(SciELO), NHS Economic Evaluation Database (NHS EED), HTA Database (Centre 
for Reviews and Dissemination (CRD)), Biblioteca Virtual em Saúde Economia da 
Saúde (BVS ECOS), SCOPUS, Web of Science, and the Sistema de Informação da Rede 
Brasileira de Avaliação de Tecnologias em Saúde (SISREBRATS) were systematically 
searched. We also performed manual search. We selected partial and full economic 
evaluation studies in cancerology, where at least one of the authors was affiliated 
to a Brazilian institution. Two authors performed study selection and data extrac-
tion independently. Disagreements were resolved through discussion or through 
consultation with a third reviewer. The study characteristics were summarized in 
figures and summary tables. Results: A total of 11946 records were identified. Fifty 
six articles met inclusion criteria, of these, 33 (59%) were a full and 23 (41%) were 
a partial economic evaluation. The cost-effectiveness analysis was the most used 
(27%). There was an increase in the number of publications over the years, especially 
after 2006. Researchers from the Southeast region of Brazil were responsible for the 
majority of the publications (82%). Cancers most frequently studied were breast can-
cer (37%), followed by cervical cancer (16%), lung cancer (12%) and colorectal cancer 
(9.0%). The technologies most studied were medications (34%). ConClusions: The 
expansion of the economic analysis literature could be explained by the growing 
demand for HTA studies by the National Policy for Health Technology Assessment 
in Brazil that may have stimulated the scientific production in this area.
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objeCtives: Crizotinib (Xalkori®) was approved for the treatment of adults with 
non-small cell lung cancer (NSCLC). The objective of this study was to illustrate the 
divergence of Health Technology Assessments in oncology by comparing the deci-
sions of the National Institute for Health and Care Excellence (NICE), the Federal 
Joint Committee (G-BA) and French National Authority for Health (HAS). Methods: 
Crizotinib’s pivotal trial (Study 1007) was analysed. NICE, G-BA and HAS reports 
were reviewed, decisions’ drivers identified and final decisions compared. Results: 
Study 1007 was a randomised open-label trial comparing crizotinib with chemo-
therapy in patients with ALK+ advanced NSCLC and who had failed one chemo-
therapy regimen. The primary endpoint was progression-free survival (PFS) and 
overall survival (OS) was a secondary endpoint. While treatment with crizotinib 
increased significantly the PFS (4.7 months) no significant improvement in OS was 
observed versus chemotherapy group (OS interim analysis). Some quality of life 
(QoL) items (e.g. chest pain, dyspnea, fatigue) were improved within the crizotinib 
group. Even though no improvement in the OS was shown, the G-BA assessed the 
crizotinib benefit as considerable based on the improvement of QoL and morbidity 
decrease. The HAS also granted crizotinib an improvement in actual benefit of III 
based on the improvements in the PFS and QoL. However, the significant gain in PFS 
was not sufficient to get positive guidance from NICE. Indeed, NICE did not recom-
mend the use of crizotinib due to the uncertainties surrounding the OS: interim OS 
data and high rate of patients “crossing-over” from standard therapy to crizotinib 
arm. ConClusions: Cross-over has become a real obstacle to appreciate oncology 
product value. While an additional benefit can be granted based on improvement 
in PFS plus morbidity and QoL results in Germany and France, products supported 
solely by an increased PFS and no change in OS may face access barriers in England.
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objeCtives: Taiwan is considered a challenging market to access, largely due to strict 
pricing and reimbursement policies. To assess the impact of health insurance reforms 
introduced in January 2013 (Second Generation National Health Insurance or 2GNHI), 
Taiwan reimbursement decisions and granted prices before and after the introduction 
were compared with major western countries. Methods: Publications of Taiwan 
NHI from March 2011 to February 2014 were searched and reimbursement decisions 
identified. The largest therapy areas, oncology and cardiovascular, which accounted 
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bACkgRound: Cancer is one of the most prevalent diseases in the UK with over 
300,000 cases every year, with breast cancer being the most common cause of 
death for adults aged 35-64.48% of all diagnosed with cancer die within 5 years. 
Cancer puts huge cost pressure on NHS resources. Multi-staged drug therapies 
involve the use of drugs to either slow down the proliferation of cancer cells or 
kill them, with variable success. The new innovative drugs are deemed to be too 
expensive for the limited benefit they may offer as the cancer may have reached 
terminal stage, after an already expensive overall course of therapy. objeCtives: 
to perform a systematic review and meta-analysis to investigate whether the drug 
cost is the main driver for the high Incremental Cost utility ratios. Methods: 
Systematic review and meta-analysis were performed to answer the research 
question. The search was concentrated to the drugs of the three most common 
cancers in the UK (breast, lung and prostate). Cardiff search database was used 
to perform the search. Two independent reviewers screened papers for inclusion, 
extracted data, and assessed the quality of reviews. PRISMA checklist was used 
by the author to undertake the meta-analysis. Results: 146 publications were 
retrieved. Final number of publications included went down to 14 [The PRISMA 
scoring for 71% of them (10 publications) were 21-24/27]. From which 25 cost 
effectiveness studies were extracted. Not every oncology drug showed high ICER 
(above £30 000), only 10 studies (45% of the publications), which contradicts the 
common perception about ICERs of oncology. More surprisingly was that eight 
(80%) of the 10 studies showed moderate cost per treatment. ConClusions: Cost 
of drug treatments is not the main driver for the high ICER (P-value: 0.982) but it 
is one of many that heavily impact the ICER value.
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objeCtives: Risk stratification based on results provided by a 21-gene assay 
(Oncotype DX ®) in early stage breast cancer can help to optimize hormone therapy 
(HT) and chemotherapy (CT) decisions, by stratifying women according to recurrence 
risk. Previous reviews addressing the issue were outdated or did not provide data on 
both overall and net decision impact regarding use of CT in this group of women. We 
aimed to perform a systematic review and meta-analysis on global decision impact 
and net change in CT use by risk category before and after assay results. Methods: 
We updated a broader systematic review (Carlson, search up to 03/12). Inclusion 
criteria were further restricted to studies with prospective data collection. Global 
decision impact was estimated as the proportion of patients whose management 
was changed after assay results were available. Net change was estimated as the 
difference between the proportion of all patients who received chemotherapy before 
and after the test. Results: Ten studies (N= 1218) met our inclusion criteria; 49.75, 
38.18 and 12.07% of patients were low, intermediate and high risk. Due to significant 
heterogeneity among studies, a random effects model is presented. Treatment deci-
sion was changed in 30.83% (95% CI 26.75 to 35.07) of all patients. From all patients, 
net change of CT use was 16% (95%CI 12-20) in the low risk group (CT+HT to HT); 
0% (-4 to 3) in the intermediate risk; and -2% (-3 to -1) in the high risk group, in this 
latter case increasing CT use (HT to CT+HT). ConClusions: Using a 21-gene assay 
showed a significant impact on treatment decisions (from 100 women, 31 will have 
their treatment optimized, and 14 less net CT overall). Its main effects consist of 
sparing chemotherapy in low risk patients, and increasing it in the high risk category.
PCN275
towardS a FraMEwork For aNalySiNg SuStaiNability oF ECoNoMiC 
valuE: tHE CaSE oF a SHort Stay PrograMME For brEaSt CaNCEr 
SurgEry CarE FivE yEarS aFtEr iMPlEMENtatioN
Ament S.1, Gillissen F.1, Maessen J.2, van der Weijden T.3, von Meyenfeldt M.2, Dirksen C.D.4
1Maastricht University, Maastricht, The Netherlands, 2Maastricht University Medical Centre, 
Maastricht, The Netherlands, 3Department of Family Medicine, CAPHRI School for Public Health 
and Primary Care’, Maastricht University, the Netherlands, Maastricht, The Netherlands, 
4Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University 
Medical Centre, Maastricht, The Netherlands
objeCtives: Critical analysis of sustainability of health care innovations is a rela-
tively new concept. The aim of this study was to provide an analytical framework 
for the evaluation of sustainability of economic value in health care. The application 
of the framework was demonstrated by using an exemplary case on a short stay 
programme for breast cancer surgery care (SSP) in the Netherlands. Methods: 
Sustainability of economic value was determined in terms of the incremental net 
monetary benefit (iNMB), in this case, five years after the end of active implementa-
tion (LATE POST) compared to early post-implementation results (POST). Economic 
value was evaluated as fully sustained if the iNMB equalled zero or was positive. 
Value of sustainability was present if the iNMB was negative. Cost and effective-
ness data of the primary implementation study were used for the POST group. The 
same data collection method was used to determine the NMB of the LATE POST 
group. Results: Economic value of the SSP was fully sustained as the mean pooled 
iNMB was € 1648 per patient. A stepwise multi-regression analysis showed that, after 
adjustment for age, NMB was higher in the LATE POST group compared to the POST 
group (B= € 1162, SE= € 714, p= 0.105, adjusted R2= 0.065). The level of sustainability 
of economic value varied between hospitals. ConClusions: The current study 
presented an analytical framework for the analysis of sustainability of economic 
value. The proposed framework provides guidance to analyse the sustainability of 
the economic value achieved in the post-implementation phase. Application of the 
framework raised issues as when to perform the analysis, the appropriate perspec-
objeCtives: In many European jurisdictions relative effectiveness assessments 
(REAs) of pharmaceuticals are performed as part of the reimbursement decision 
making process. Collaboration in the production of these assessments across 
jurisdictions prevent duplication of information in various jurisdictions and save 
resources accordingly. A first pilot of a joint REA of pharmaceutical (pazopanib 
for the treatment of renal cell carcinoma) was published in 2011. The aim of this 
study is to verify how informative the joint REA is for national assessments by 
comparing the joint REA of pazopanib with nationally produced assessments on 
the same topic. Methods: National assessments from European countries were 
identified through a literature search and an email request to health technology 
assessment (HTA) organisations. Data were abstracted from the assessments using 
a structured data abstraction form including questions about the criteria assessed, 
the scope, the evidence included, the assessment of the evidence and the outcome 
of the assessment. The abstracted data were validated by representatives from the 
authoring organisations. Results: In total five jurisdiction specific HTA reports, 
available in English language, were included (Belgium, England/Wales, France, The 
Netherlands and Scotland). Four out of five reports included a positive recommen-
dation on pazopanib. Although the general methods (indication, main comparator, 
main endpoints, main trial) were similar the details of the assessment (e.g. exact 
wording of indication, additional comparators, additional trials included, method 
of indirect comparison) varied. The joint REA included nearly all of the compara-
tors, endpoints, trials and methods of analysis that were used in the jurisdiction 
specific REA reports. ConClusions: Although there is some variety in the number 
of comparators and methods for analysis for the included jurisdiction specific REA 
reports on pazopanib, it seems feasible to capture most of these in an extensive joint 
REA. This suggests that joint REAs may serve their role as a basis for national REAs.
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objeCtives: Human Epididymis Protein 4 (HE4) is diagnostic test that diagnosis 
ovarian cacner with CA125 for pelvic mass patients or monitoring of response to 
treatment, prognosis and reccurence for ovarian cancer patients. So We assess the 
safety and efficacy of HE4 test. Methods: We searched eight domestic databases and 
other foreign databases such as Ovid-MEDLINE, Ovid-EMBASE, and Cochrane Library. 
The 44 articles were included in this review. Two reviewers independently assessed 
selection of studies and quality assessment of each study. Quality assessment tool 
was used SIGN. The meta analysis results reported pooled sensitivity and specificity.  
Results sAFetY: HE4 was conducted with patient’s serum sample, so safety is same 
as a blood sampling. Thererfore, there is no safety problem. EFFICACY: 1) HE4 vs 
CA125: In 10studies, the pooled sensitivity and specificity were HE4 0.771, 0.931 and 
CA125 0.839, 0.677.6 studies with suspected ovarian cancer were included, pooled 
sensitivity and specificity were HE4 0.745, 0.946, CA125 0.819, 0.676. In two studies, 
hazard ratio of progression-free survival and overall survival for HE4 were higher 
than CA125.2) ROMA vs CA125: In 6studies, the pooled sensitivity and specificity were 
ROMA 0.865, 0.809 and CA125 0.843, 0.672. Three studies with suspected ovarian can-
cer were included, pooled sensitivity and specificity were ROMA 0.833, 0.857, CA125 
0.817, 0.664. In one study, hazard ratio of progression-free survival and overall survival 
for ROMA were higher than CA125. ConClusions: Although sensitivity of HE4 was 
lower than CA125, but specificity was higher than CA125. So HE4 supplemented lower 
specificity of CA125. Beause sensitivity and specificity of ROMA were highter than 
CA125, lower sensitivity of HE4 were supplement with CA125. Also prognostic value 
of this test looks like it can be used to predict recurrence in patients diagonised with 
epithelial ovarian cancer, it’s hard to generalize it will current research outcomes.
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objeCtives: In Germany third parties like manufacturers, physician associations, 
medical societies, or industry organisations are allowed to comment on the early 
benefit assessments (EBA) of drugs by submitting written statements (WS) and 
attending oral hearings (OH) before the Federal Joint Committee (G-BA) decides on 
a resolution. This review assesses the number of WS and OH participants of cancer 
drugs’ EBA and evaluates trends in third party participation (TPP). Methods: The 
status of cancer drugs’ EBA and associated documents from 2011 until May 2014 
were retrived from the G-BA website. All completed assessments were included if 
a summary documentation including the OH protocoll and all WS was available. 
Information on number and category of third parties submitting WS or attend-
ing OH were extracted from the summary documentation, categorized and ana-
lysed. Results: Until May 2014 28 cancer drugs’ EBA were started and 25 completed. 
Summary documentation was available for 14 (56%) completed assessments. The 
mean number of submitted WS was 9.1 (range 4-16). The mean number of third 
parties in OH was 5.9 (range 3-9). In all EBA the manufacturer submitted WS and 
participated in the OH. Representatives of at least one competitor and pharmaceu-
tical industry organizations each were present in all OH. Apart from one EBA, for 
which no dossier was available, medical societies always turned in WS and attended 
11 (85%) OH. In the beginning of the EBA process the number of submitted WS was 
slightly higher. Overall, no trend for TPP in OH was identified. ConClusions: In 
Germany TPP in cancer drugs’ EBA is broadly used by both medical societies and 
the pharmaceutical industry. Further research is required to identify reasons why 
medical societies do not attend OH although a WS was handed in.
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